Evidence map›Paper›PMID 41304406›Full record

ArticlePolymers2025

Enzymatic Degradation of PLA: Preferential Degradation of the Amorphous Fraction.

Sarita Shrestha, Michael Snowdon, David B Levin

Abstract read
In one paragraph

Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sarita ShresthaDepartment of Biosystem Engineering, University of Manitoba, Fort Garry Campus, 75 Chancellors Circle, Winnipeg, MB R3T 5V6, Canada.ORCID 0000-0002-0010-2408
Michael SnowdonSustainable Packaging Team, Automotive and Surface Transportation, National Research Council Canada, Advanced Manufacturing Research Facility, 2690 Red Fife Road, Centreport, Winnipeg, MB R4B 0A6, Canada.ORCID 0000-0003-3541-3684
David B LevinDepartment of Biosystem Engineering, University of Manitoba, Fort Garry Campus, 75 Chancellors Circle, Winnipeg, MB R3T 5V6, Canada.ORCID 0000-0003-4533-500X

Funding

National Research Council (NRC) of Canada AM-134-1
6 · The paper itself

Abstract

Polylactic acid (PLA), a widely used biobased biopolymer, is highly resistant to biodegradation under ambient conditions, contributing to persistent plastic pollution and posing potential environmental and health risks. This study investigates the enzymatic degradation of PLA by Proteinase K, a proteolytic hydrolase enzyme with the ability to degrade PLA, and explores the underlying mechanisms for degradation. Both amorphous and semi-crystalline PLA were treated with Proteinase K (2 mg/mL) at 37 °C over varying time periods. PLA degradation was evaluated using multiple techniques, including weight loss measurement, pH reduction, quantification of lactic acid monomer release by High-Performance Liquid Chromatography (HPLC), surface morphology analysis through Scanning Electron Microscopy (SEM), changes in thermal properties by Differential Scanning Calorimetry (DSC), and structural changes by X-Ray Diffraction (XRD). The data revealed that the degradation of amorphous regions of the PLA polymer was faster and more extensive than the crystalline regions of the polymer. Repeated enzymatic treatments significantly enhanced the degradation rate. Furthermore, Proteinase K showed a clear preference for degrading amorphous regions of the PLA, as evidenced by higher weight loss, sharper pH decline, higher lactic acid production, and more pronounced surface disruptions, such as visible gaps between degraded oligomer structures.

Indexed as

enzymatic degradationPolylactic acid (PLA)polymer structureProteinase K

Identifiers

PMID41304406
PMCPMC12655971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.